DeepHealth Advances with Key Regulatory Approvals for AI Imaging Solutions
DeepHealth has reached significant regulatory approvals for its AI-driven imaging technologies, strengthening its position in the radiology sector. The company has achieved CE Marking for its Brain Health and Brain Age tools, which are part of the Neuro Suite, as well as for its LumbarMR solution. Additionally, its Prostate AI solution has received both FDA 510(k) clearance and CE Marking.
DeepHealth's successful regulatory achievements underscore the company's commitment to enhancing medical imaging through AI. According to Niccolo Stefani, MD, Business and Product Leader at DeepHealth, these clearances exemplify the company's dedication to advancing its clinical AI solutions to improve diagnostic accuracy and efficiency in radiology.
Brain Health and Brain Age Gain CE Marking
The Neuro Suite’s Brain Health and Brain Age tools have been designed to automate and standardize neuroimaging analysis. These tools enable clinicians to provide proactive care by using normative data comparisons and tracking changes over time. Brain Health introduces a novel algorithm for White Matter Hyperintensity (WMH) detection, aiming to eliminate manual processes. In addition, Brain Age expands AI’s role in identifying brain structures like the hippocampus and subcortical regions, which is critical for memory and dementia evaluations. With a reported 92% sensitivity for detecting hippocampal atrophy linked to Alzheimer’s disease, these solutions are poised to enhance preclinical stage diagnostics.
Both tools are FDA 510(k) cleared and actively used across various outpatient sites managed by RadNet in the United States. As Kevin L. Berger, MD, a diagnostic radiologist, notes, the integration of these AI tools significantly boosts workflow efficiency and diagnostic confidence.
CE Marking for LumbarMR
The LumbarMR tool is a recent addition to DeepHealth's portfolio following the acquisition of Gleamer SAS. It is tailored to support radiologists in diagnosing low back pain through lumbar spine MRI by automatically detecting and reporting key pathologies. This AI solution has demonstrated up to 94% sensitivity and a 17% reduction in reporting time per exam compared to traditional methods without AI assistance.
Prostate AI Secures FDA and CE Approvals
DeepHealth’s Prostate AI solution, a component of the Prostate Suite, offers a comprehensive approach to prostate cancer detection and assessment. It streamlines the prostate MRI workflow by integrating automated lesion detection, risk classification, and PSA density calculations into a PI-RADS-compliant reporting system. This solution is compatible with 11 fusion biopsy systems, facilitating more consistent clinical evaluations among radiologists.
Field applications of Prostate AI have shown an increase in lesion detection by 27%, as well as a 65% reduction in variability among radiologists and a 37% reduction in workflow time for biopsy-recommended cases. The solution is a key part of the U.K.'s TRANSFORM program, the largest prostate screening initiative aiming to analyze over 100,000 scans.
Pr. Francesco Giganti, Associate Professor of Radiology at University College London, emphasizes the significant impact of AI technologies like the Prostate Suite in expanding access to prostate cancer screening and ensuring timely, accurate care.
These regulatory accomplishments signal DeepHealth’s continuing influence in providing advanced AI-enabled solutions that support healthcare professionals and improve patient outcomes across neuro, lumbar, and prostate imaging.